Prosecution Insights
Last updated: April 19, 2026
Application No. 18/015,746

MONOTERPENOID AND PHENYLPROPANOID CARBONATE ESTERS AND METHODS OF THEIR MAKING AND USE AS REPELLENTS

Non-Final OA §102§112
Filed
Jan 12, 2023
Examiner
COUGHLIN, MATTHEW P
Art Unit
1626
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Iowa State University Research Foundation Inc.
OA Round
3 (Non-Final)
71%
Grant Probability
Favorable
3-4
OA Rounds
2y 5m
To Grant
84%
With Interview

Examiner Intelligence

Grants 71% — above average
71%
Career Allow Rate
702 granted / 984 resolved
+11.3% vs TC avg
Moderate +12% lift
Without
With
+12.2%
Interview Lift
resolved cases with interview
Typical timeline
2y 5m
Avg Prosecution
48 currently pending
Career history
1032
Total Applications
across all art units

Statute-Specific Performance

§101
1.7%
-38.3% vs TC avg
§103
24.9%
-15.1% vs TC avg
§102
20.4%
-19.6% vs TC avg
§112
30.3%
-9.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 984 resolved cases

Office Action

§102 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Claims 1, 6-8, 10, 12, 14, 16, 21 and 23-25 are pending in the application. Claims 1, 6, 7, 16 and 21 are rejected. Claims 8, 10, 12, 14 and 23-25 are withdrawn from further consideration. Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on January 29th, 2026 has been entered. Response to Amendment / Argument Rejections made in the previous Office Action that have been overcome by Applicant's amendments to the claims. Election/Restrictions The search and examination has been extended in view of MPEP 803.02 to include the species cited below under 35 USC 102. Additional species (besides the elected species) are withdrawn from consideration. An additional issue under 35 USC 112(d) was discovered incidental to the expanded search and is presented below. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claim 7 is rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. The fourth and sixth structures recited in claim 7 do not fall within the scope of its parent claim based on the structure of R1. The corresponding option for R1 has been struckthrough in claim 1 in the amendment dated January 29th, 2026. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1, 6, 7, 16 and 21 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Bergbreiter et al. Tetrahedron Letters 1997, 38, 7843-7846. BergBreiter et al. teach the following compounds on page 66: PNG media_image1.png 201 302 media_image1.png Greyscale . The compound 7c is embraced by formula (I) of claim 1 where R1 is the last option depicted in claim 1 and R2 is C2 alkyl. Compound 7c further anticipates claim 6 and claim 7 (fourth to last structure). Regarding instant claims 16 and 21, the prior art teaches that the compounds were used in reactions and that “The reactions were carried out homogeneously in H20 or mixed solvents THF/H20, CH3CN/H20 or EtOH/H20” where water can be considered a carrier and irrespective of how the prior art compounds were applied, a solution can be considered a spray. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to MATTHEW P COUGHLIN whose telephone number is (571)270-1311. The examiner can normally be reached Monday - Friday, 10 am - 6 pm EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Renee Claytor can be reached at 571-272-8394. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MATTHEW P COUGHLIN/Primary Examiner, Art Unit 1626
Read full office action

Prosecution Timeline

Jan 12, 2023
Application Filed
Jun 21, 2025
Non-Final Rejection — §102, §112
Sep 15, 2025
Response Filed
Sep 28, 2025
Final Rejection — §102, §112
Jan 29, 2026
Request for Continued Examination
Feb 02, 2026
Response after Non-Final Action
Feb 17, 2026
Non-Final Rejection — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600706
METHOD FOR MANUFACTURING LOW-VISCOSITY HARDENER
2y 5m to grant Granted Apr 14, 2026
Patent 12600708
PRODRUG COMPOUNDS OF 3,4-METHYLENEDIOXYMETHAMPHETAMINE (MDMA) AND METHODS OF SYNTHESIZING THE SAME
2y 5m to grant Granted Apr 14, 2026
Patent 12577236
NOVEL PROCESSES FOR PREPARATION OF TEZACAFTOR
2y 5m to grant Granted Mar 17, 2026
Patent 12577220
METHOD FOR MANUFACTURING (2,2-DIMETHYL-1,3-DIOXOLAN-4-YL)METHANOL
2y 5m to grant Granted Mar 17, 2026
Patent 12559503
ANTHELMINTIC AZA-BENZOTHIOPHENE AND AZA-BENZOFURAN COMPOUNDS
2y 5m to grant Granted Feb 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
71%
Grant Probability
84%
With Interview (+12.2%)
2y 5m
Median Time to Grant
High
PTA Risk
Based on 984 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month